ACTL9 Inhibitors
ACTL9 inhibitors represent a class of chemical compounds that specifically target and inhibit the function of the ACTL9 protein, a member of the actin-like protein family. Actin-like proteins are cytoskeletal components that are critical in maintaining cell shape, facilitating motility, and supporting intracellular transport. ACTL9, in particular, is associated with various regulatory pathways linked to cellular processes involving actin dynamics. By modulating ACTL9 activity, these inhibitors can alter actin-based processes such as cellular organization, division, and signal transduction. Structurally, ACTL9 inhibitors often contain moieties designed to interact specifically with key binding domains on the ACTL9 protein, blocking its ability to participate in actin polymerization or to bind with other associated proteins.
The development of ACTL9 inhibitors often involves extensive structure-activity relationship (SAR) studies to fine-tune the chemical interactions between the inhibitor and the ACTL9 protein. These studies focus on optimizing molecular properties such as binding affinity, selectivity, and stability to ensure precise inhibition of ACTL9 without off-target effects on other actin-related proteins. The synthesis of such inhibitors may involve diverse synthetic organic chemistry techniques, including strategic use of heterocyclic cores, aromatic substitutions, and functional group modifications to enhance their binding characteristics. The regulation of ACTL9 activity by these inhibitors offers a unique window into cellular actin mechanics, allowing for the study of dynamic cellular functions such as cytoskeletal reorganization, intracellular trafficking, and morphogenesis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A inhibits histone deacetylase activity, which could lead to an open chromatin structure and reduced binding of transcriptional repressors to the ACTL9 promoter, downregulating its transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This compound incorporates into DNA, inhibiting DNA methyltransferases. This inhibition could result in hypomethylation of the ACTL9 promoter, decreasing the transcriptional activity of the gene. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Actinomycin D binds to DNA at the transcription initiation complex, obstructing elongation and potentially causing a decrease in ACTL9 mRNA synthesis. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
By binding to GC-rich DNA sequences, Mithramycin A could prevent transcription factors from binding to the ACTL9 promoter, leading to a decrease in its gene expression. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine's DNA intercalating activity could disrupt the transcriptional machinery necessary for the expression of the ACTL9 gene, leading to a reduction in its RNA levels. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $42.00 $185.00 $310.00 $650.00 | 6 | |
DRB specifically inhibits the phosphorylation of RNA Polymerase II, which is crucial for elongation during transcription, potentially resulting in the decreased expression of the ACTL9 gene. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
α-Amanitin's inhibition of RNA polymerase II could lead to a specific decrease in the elongation phase of mRNA synthesis for genes like ACTL9, downregulating its expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which could lead to a reduced translation of transcriptional activators necessary for ACTL9 expression, thereby diminishing its expression. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol could downregulate the expression of the ACTL9 gene by inhibiting the activity of specific transcription factors or coactivators required for its transcription. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin may downregulate ACTL9 by inhibiting transcription factors or kinases that are upstream activators of the gene expression pathway for ACTL9. | ||||||